Pilot study of stereotactic body radiotherapy for huge hepatocellular carcinoma unsuitable for other therapies

Tumori

Volumn 96, Issue 1, 2010, Pages 65-70

  Shin, Young Joo ^a   Kim, Mi Sook ^a   Yoo, Seong Yul ^a   Cho, Chul Koo ^a   Seo, Young Seok ^a   Kang, Jin Kyu ^a   Park, Su Cheol ^a   Han, Chul Ju ^a   Kim, Sang Beom ^a   Lee, Byong Hee ^a   Lee, Dong Han ^a  

^a Korea Cancer Center Hospital   (South Korea)

Author keywords

Huge hepatocellular carcinoma; Stereotactic body radiation therapy; Transcatheter arterial chemoembolization

Indexed keywords

ADULT; ARTICLE; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CHEMOEMBOLIZATION; CLINICAL ARTICLE; CLINICAL ASSESSMENT; DEATH; DISEASE DURATION; FOLLOW UP; HUMAN; LIVER CELL CARCINOMA; LIVER FUNCTION; LOBECTOMY; NAUSEA; PILOT STUDY; PLEURA EFFUSION; PROGRESSION FREE SURVIVAL; RADIATION DOSE FRACTIONATION; STEREOTACTIC BODY RADIATION THERAPY; TOXICITY; TREATMENT FAILURE; TREATMENT RESPONSE;

ADULT; CARCINOMA, HEPATOCELLULAR; EMBOLIZATION, THERAPEUTIC; FEMALE; HEPATIC ARTERY; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; PILOT PROJECTS; POSITRON-EMISSION TOMOGRAPHY; RADIOSURGERY; RADIOTHERAPY DOSAGE; RADIOTHERAPY PLANNING, COMPUTER-ASSISTED; SURVIVAL ANALYSIS; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 77950838125     PISSN: 03008916     EISSN: None     Source Type: Journal    
DOI: 10.1700/479.5653     Document Type: Article

References (19)

1. Parkin DM, Bray F, Ferlay J, Pisani P: Global cancer statistics, 2002. CA Cancer J Clin, 55: 74-108, 2005.
2. Nagasue N, Kohno H, Chang YC, Taniura H, Yamanoi A, Uchida M, Kimoto T, Takemoto Y, Nakamura T, Yukaya H: Liver resection for hepatocellular carcinoma. Results of 229 consecutive patients during 11 years. Ann Surg, 217: 375-384, 1993. (Pubitemid 23115341)
3. Abdel-Wahab M, Sultan A, el-Ghawalby A, Fathy O, el- Ebidy G, Abo-Zeid M, Aboel-Enin A, Abdallah T, Fouad A, el-Fiky A, Gadel-Hak N, Ezzat F: Is resection for large hepatocellular carcinoma in cirrhotic patients beneficial? Study of 38 cases. Hepatogastroenterology, 48: 757-761, 2001.
4. Poon RT, Ngan H, Lo CM, Liu CL, Fan ST,Wong J: Transarterial chemoembolization for inoperable hepatocellular carcinoma and postresection intrahepatic recurrence. J Surg Oncol, 73: 109-114, 2000. (Pubitemid 30123735)
5. Mendez Romero A,WunderinkW,Hussain SM,De Pooter JA, Heijmen BJ,Nowak PC,Nuyttens JJ, Brandwijk RP,Verhoef C, Ijzermans JN, Levendag PC: Stereotactic body radiation therapy for primary andmetastatic liver tumors: A single institution phase i-ii study. Acta Oncol, 45: 831-837, 2006.
6. Tse RV, Hawkins M, Lockwood G, Kim JJ, Cummings B, Knox J, ShermanM, Dawson LA: Phase I study of individualized stereotactic body radiotherapy for hepatocellular carcinoma and intrahepatic cholangiocarcinoma. J Clin Oncol, 26: 657-664, 2008.
7. ScorsettiM, BignardiM: Conformal and stereotactic radiotherapy in hepatocellular carcinoma. Ann Ital Chir, 79: 107-110, 2008.
8. Bruix J, Sherman M, Llovet JM, Beaugrand M, Lencioni R, Burroughs AK, Christensen E, Pagliaro L, Colombo M, Rodes J, EASL Panel of Experts on HCC: Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol, 35: 421-430, 2001.
9. Kim JG, Lee DH, KimMS: A study on the reduction of organ motion from respiration. Korean J Med Phys, 15: 179-185, 2004.
10. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L,Verweij J,Van GlabbekeM, van Oosterom AT, Christian MC, Gwyther SG: New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst, 92: 205-216, 2000.
11. Trotti A, Colevas AD, Setser A, Rusch V, Jaques D, Budach V, Langer C, Murphy B, Cumberlin R, Coleman CN, Rubin P: CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol, 13: 176-181, 2003. (Pubitemid 36962641)
12. Pandey D, Lee KH, Wai CT, Wagholikar G, Tan KC: Long term outcome and prognostic factors for large hepatocellular carcinoma (10 cm or more) after surgical resection. Ann Surg Oncol, 14: 2817-2823, 2007.
13. Pawlik TM, Delman KA, Vauthey JN, Nagorney DM, Ng IO, Ikai I,YamaokaY, Belghiti J, LauwersGY, Poon RT, Abdalla EK: Tumor size predicts vascular invasion and histologic grade: Implications for selection of surgical treatment for hepatocellular carcinoma. Liver Transpl, 11: 1086-1092, 2005.
14. Mok KT,Wang BW, Lo GH, Liang HL, Liu SI, Chou NH, Tsai CC, Chen IS, Yeh MH, Chen YC: Multimodality management of hepatocellular carcinoma larger than 10 cm. J Am Coll Surg, 197: 730-738, 2003.
15. Lee SG, Hwang S, Jung JP, Lee YJ, Kim KH, Ahn CS: Outcome of patients with huge hepatocellular carcinoma after primary resection and treatment of recurrent lesions. Br J Surg, 94: 320-326, 2007.
16. Herfarth KK, Debus J, Lohr F, Bahner ML, Rhein B, Fritz P, Hoss A, Schlegel W, Wannenmacher MF: Stereotactic single- dose radiation therapy of liver tumors: results of a phase I/II trial. J Clin Oncol, 19: 164-170, 2001.
17. Wulf J, Hadinger U, Oppitz U, ThieleW, Ness-Dourdoumas R, Flentje M: Stereotactic radiotherapy of targets in the lung and liver. Strahlenther Onkol, 177: 645-655, 2001.
18. Yaes RJ, Kalend A: Local stemcell depletionmodel for radiation myelitis. Int J Radiat Oncol Biol Phys, 14: 1247-1259, 1988.
19. Schefter TE, Kavanagh BD, Timmerman RD, Cardenes HR, Baron A, Gaspar LE: A phase I trial of stereotactic body radiation therapy (SBRT) for liver metastases. Int J Radiat Oncol Biol Phys, 62: 1371-1378, 2005.